What, in your assessment, were the most significant primary and secondary end points achieved in the ASPEN trial evaluating the safety and efficacy of brensocatib in NCFBE?

Anne E. O’Donnell, MD

The Nehemiah and Naomi Cohen Chair in Pulmonary Disease ResearchProfessor of MedicineInterim Chair, Department of MedicineChief, Division of Pulmonary, Critical Care and Sleep MedicineGeorgetown University Medical Center/Medstar Georgetown ...